Apricus Biosciences - könnte interessant werden
Seite 2 von 4 Neuester Beitrag: 25.04.21 00:40 | ||||
Eröffnet am: | 16.02.12 17:05 | von: Bootsektor_1 | Anzahl Beiträge: | 100 |
Neuester Beitrag: | 25.04.21 00:40 | von: Jennifersydc. | Leser gesamt: | 36.736 |
Forum: | Hot-Stocks | Leser heute: | 17 | |
Bewertet mit: | ||||
Seite: < 1 | | 3 | 4 > |
Richard Pascoe, Chief Executive Officer of Apricus, commented, "We are pleased to announce Bracco's launch of Vitaros, the first on-demand topical treatment, in Italy, Europe's second largest ED treatment market which Bracco estimates to be approximately $135 million. As another contributor towards the positive momentum of commercialization by our partners, which recently produced 103% growth in units quarter over quarter, Bracco plans to implement a strong promotional strategy targeted at physicians across Italy. With this news, the product is now launched in the five largest markets in Europe."
In December 2010, Apricus signed an exclusive license agreement with Bracco to market Vitaros, in Italy, Vatican City and San Marino (the "Territory"). Under the terms of the agreement, Apricus has received $1.3 million in up-front and milestone payments from Bracco. Apricus is also eligible to receive milestone payments on future sales, plus double-digit tiered royalties based on Bracco's net sales of the product in the Territory. In exchange, Bracco has the exclusive right to commercialize Vitaros in the Territory. In addition, Bracco has agreed to certain minimum marketing commitments for Vitaros.
Im April erwartet
https://clinicaltrials.gov/ct2/show/record/...term=Apricus&rank=2
Laut der neusten Präsentation vom 08.02.2016:
Fispemifene top-line Phase 2b data in Q1 2016
http://phx.corporate-ir.net/...NoaWxkSUQ9MzIyMTk4fFR5cGU9MQ==&t=1
werden morgen veröffentlicht. Sarissa besitzt nun über 30 % Anteile an Apricus:
http://secfilings.nasdaq.com/...FA&RcvdDate=3%2F7%2F2016&pdf=wir
LG, biotech
Anyone listen to today's webcast? NDA for Vitaros US target in Q3 2016, with hope for approval 6 months hence Reduce spending by 30% by streamlining Capital needs greatly reduced Operating income needs and length of sustainability will be recalculated No mention of milestones RayVa orphan status feedback will be pursued, forgot what Pascoe said about timeframe for 2B Organic growth of Vitaros in European countries already launched Grow Vitaros Europe with additional launches in approved countries and seek approval in additional countries Well this certainly was bad news today, but I came here for Vitaros, so I guess I'll just have to suck it up and see how the original instincts line up... |
http://www.siliconinvestor.com/readmsg.aspx?msgid=30520192
auf die nächsten Ereignisse:
http://ir.apricusbio.com/...x.zhtml?c=118007&p=irol-presentations
Apricus Biosciences, Inc. Wednesday said plans to prioritize the Vitaros commercial and regulatory activities and to deprioritize all other pipeline programs. The company expects 30 percent reduction in staff and cash-based operating expenses. It will also cut short the size of the director board and cash compensation.
http://www.nasdaq.com/article/...ff-operating-expenses-20160406-00250
http://www.nasdaq.com/press-release/...rmaceuticals-in-20160725-00181
http://www.nasdaq.com/press-release/...-dysfunction-in-20160727-00295
Completion of Transfer of Vitaros® German Marketing Authorization to Ferring Pharmaceuticals
http://www.nasdaq.com/press-release/...uthorization-to-20160810-00205
Apricus Biosciences Announces Completion of Transfer of the United Kingdom Marketing Authorization for Vitaros® to Ferring Pharmaceuticals
http://www.nasdaq.com/press-release/...g-authorization-20160815-00151
Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals
http://www.nasdaq.com/press-release/...pharmaceuticals-20170308-01117